What items should be assessed when calculating the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

SLEDAI Assessment Components

The SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) evaluates 24 clinical and laboratory variables across 9 organ systems, with weighted scores reflecting disease severity in each domain. 1

Core Assessment Domains and Specific Items to Evaluate

Central Nervous System (Weight: 8 points)

  • Seizures - new onset or recent
  • Psychosis - altered ability to function in normal activity due to severe disturbance in perception of reality
  • Organic brain syndrome - altered mental function with impaired orientation, memory, or other intellectual function
  • Visual disturbance - retinal changes of SLE (cytoid bodies, retinal hemorrhages, serous exudate or hemorrhages in choroid, optic neuritis)
  • Cranial nerve disorder - new onset of sensory or motor neuropathy involving cranial nerves
  • Lupus headache - severe, persistent, unresponsive to narcotic analgesia

Vascular System (Weight: 8 points)

  • Cerebrovascular accident - new onset of cerebrovascular accident(s)
  • Vasculitis - ulceration, gangrene, tender finger nodules, periungual infarction, splinter hemorrhages, or biopsy/angiogram proof of vasculitis

Renal System (Weight: 4 points)

  • Hematuria - >5 RBCs/hpf, excluding stone, infection, or other causes
  • Proteinuria - >0.5 g/24 hours (new onset or recent increase >0.5 g/24h)
  • Pyuria - >5 WBCs/hpf, excluding infection
  • Urinary casts - heme-granular or RBC casts

Musculoskeletal System (Weight: 4 points)

  • Arthritis - more than 2 joints with pain and signs of inflammation (tenderness, swelling, or effusion)
  • Myositis - proximal muscle aching/weakness associated with elevated CPK/aldolase or EMG changes or biopsy showing myositis

Serosal Involvement (Weight: 2 points)

  • Pleuritis - pleuritic chest pain with pleural rub, effusion, or pleural thickening
  • Pericarditis - pericardial pain with at least one of: rub, effusion, EKG or echocardiogram confirmation

Dermatologic Manifestations (Weight: 2 points)

  • New or recurrent inflammatory rash
  • Alopecia - new onset or recurrent abnormal, patchy or diffuse hair loss
  • Mucosal ulcers - oral or nasal ulcerations

Immunologic Parameters (Weight: 2 points)

  • Anti-dsDNA antibodies - elevated above laboratory reference range (or >25% increase if previously elevated)
  • Low complement - decreased C3, C4, or CH50 below lower limit of normal
  • Anti-Sm antibodies - presence of antibody to Sm nuclear antigen

Constitutional Symptoms (Weight: 1 point)

  • Fever - >38°C, excluding infectious causes

Hematologic Abnormalities (Weight: 1 point)

  • Thrombocytopenia - <100,000 platelets/mm³
  • Leukopenia - <3,000 WBCs/mm³ (excluding drug causes)

Critical Assessment Parameters

Laboratory investigations required 2:

  • Complete blood count with differential
  • Urinalysis with microscopy
  • Urine protein/creatinine ratio (or 24-hour proteinuria)
  • Serum creatinine or eGFR
  • Anti-dsDNA antibodies
  • Complement levels (C3, C4, CH50)
  • ESR and CRP

Clinical evaluation must include 2:

  • Focused neuropsychiatric history (seizures, paresthesias, numbness, weakness, headache, cognitive difficulties with multitasking, memory problems)
  • Skin examination for rash type and distribution
  • Joint examination for synovitis
  • Cardiovascular examination for pericardial rub
  • Pulmonary examination for pleural involvement

Scoring Interpretation

The SLEDAI generates scores from 0-105 (though scores rarely exceed 45 in practice). Each manifestation is scored only if present within the preceding 10 days 1. The weighted system reflects clinical consensus on organ system severity, with CNS and vascular manifestations carrying the highest weight due to their impact on morbidity and mortality.

Disease activity stratification 3, 4:

  • SLEDAI ≤3 on antimalarials = low disease activity target
  • SLEDAI ≤4 with PGA ≤1 and prednisone ≤7.5 mg = acceptable alternative low disease activity state
  • Higher scores indicate need for treatment intensification

Common Pitfalls

Do not confuse SLEDAI with damage indices - SLEDAI measures reversible disease activity, not irreversible organ damage (which is captured by the SLICC/ACR Damage Index) 5.

Ensure temporal accuracy - only manifestations present in the preceding 10 days count toward the score 1.

Distinguish SLE activity from other causes - fever must exclude infection, cytopenias must exclude drug effects, and neurologic symptoms must exclude non-SLE etiologies before scoring.

References

Related Questions

What is the SLE Disease Activity Index (SLEDAI) score for a patient with polyarthritis of the wrists, metacarpophalangeal and proximal interphalangeal joints, malar facial rash, low‑grade fever, and proteinuric nephritis (foamy urine and bilateral edema)?
What is the recommended clinical guide for diagnosing and treating systemic lupus erythematosus?
What is the appropriate management for a 40-year-old patient with systemic lupus erythematosus presenting with severe arthritis?
In a patient with systemic lupus erythematosus presenting with a blood pressure of 148/94 mmHg and a temperature of 37.8 °C, what is the appropriate initial management?
Can electroconvulsive therapy (ECT) be safely administered to a patient with systemic lupus erythematosus?
What is the appropriate management for a patient with acute kidney injury (creatinine 5.08 mg/dL, eGFR 10 mL/min/1.73 m², BUN 91 mg/dL, hyponatremia, metabolic acidosis) and no acute abdominal or pulmonary findings?
Is it safe to start pregabalin (Lyrica) for diabetic peripheral neuropathy in a patient with uncontrolled diabetes, asthma, hyperlipidemia, gout (not taking allopurinol), who is currently taking atorvastatin, benralizumab (Fasenra) subcutaneous injection, furosemide, glipizide, montelukast, insulin aspart (Novolog), and omeprazole?
What are the risks and recommended precautions for using hydroxyzine in a patient with anorexia nervosa, major depressive disorder, and anxiety?
Why does adenosine provoke a cough reflex?
What oral therapeutic options are available for acne vulgaris and how long has each been in clinical use?
What are the years of discovery for each of the following acne therapies: doxycycline, minocycline, sarecycline, oral isotretinoin, combined oral contraceptives (estrogen‑progestin pills), spironolactone, and dapsone?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.